MedTrace Logo

Flortaucipir 18F PET Imaging in BIOCARD Study

NCT03052972 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-09-25

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the imaging characteristics of Flortaucipir (18F-AV-1451) in subjects who participated in the Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study at Johns Hopkins University.

Conditions

Interventions

DRUG

Flortaucipir F18

370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose

PROCEDURE

Brain PET scan

positron emission tomography (PET) scan of the brain

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Medical Director · Avid Radiopharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-23
Primary Completion
2018-08-14
Completion
2018-08-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052972 on ClinicalTrials.gov